Teva Proves Its Decade-Hold Status With Massive Funding

Health and Healthcare

Published: July 31, 2015 1:44 pm

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has secured financing of $33.75 billion to help the company pay for its $40 billion or so acquisition of the generic business of Allergan PLC (NYSE: AGN).

Teva’s release said that it has entered into commitment letters with Bank of America Merrill Lynch, Barclays Bank PLC, BNP Paribas, Citi, Credit Suisse, HSBC, Mizuho Bank, Morgan Stanley Senior Funding, RBC Capital Markets and Sumitomo Mitsui Banking Corporation.

Commitment letters have been represented as offering Teva the following:

up to $27,000,000,000 in loans under a senior unsecured Bridge Loan Credit Facility
and up to $6,750,000,000 in loans under an Equity Bridge Loan Credit Facility.

While Teva noted that these commitments are subject to customary conditions, it is always impressive when a company can say that it secured tens of billions of dollars in financing. This is just one of the reasons that Teva was included as one of the 10 Stocks To Own for the Next Decade in a 24/7 Wall St. exclusive.

The customary conditions include the negotiation of definitive financing agreements and other conditions. News of this sort may not be the biggest market mover, but how many companies do you see that issue press releases saying they secured over $30 billion in funding?

So, did Mylan NV (NASDAQ: MYL) lose out here? The company successfully thwarted Teva’s buyout attempts. Some concerns may have been over financing, and some may have been regulatory. Either way, Mylan did not want to be acquired by Teva – and its shares paid a high price for it. When Teva’s deal for Allergan surfaced this last Monday, Mylan shares went from a Friday close of $65.94 down by a sharp 14.5% to $56.37.

Teva shares were down 0.5% at $68.73 on Friday afternoon. Its consensus analyst price target is now $75.50 and the 52-week trading range is $47.36 to $72.31.

ALSO READ: 4 Top Analyst Picks With Very Predictable Earnings

Are You Ahead, or Behind on Retirement?

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: am I ahead, or behind on my goals?

Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With Zoe Financial’s free matching tool, you can connect with trusted financial advisors in minutes.

Why wait? Click here to get started today!